[ad_1]
Tuesday and the New York Times fell bomb report of patents surrounding Moderna Covid-19 vaccine. After a four-year agreement with the US National Institutes of Health, Moderna issued a warrant against the most important part of its vaccine, and did so with the exception of the names of only its scientists. To the surprise of the NIH, all its scientists were removed from the patent, which could have far-reaching consequences. Had the government been involved in filtering, then the US could have provided technical approval, which would have enabled it to be released more quickly and in large quantities, as well as in developing countries where vaccination rates remain low. If the patent is approved as it was written, this could give Moderna exclusive control over this technology – as well as a multi-billion dollar profit. Many scientists view Moderna’s move as unreliable.
Today on RE: WIRID, our chief secretary Maryn McKenna sat down with Moderna CEO Stéphane Bancel, along with Nahid Bhadelia, a world-renowned infectious disease doctor. Bhadelia is the executive director of Boston University’s Center for Emerging Infectious Diseases Policy and Research, and a partner of National Emerging Infectious Diseases Laboratories, a major research center in BU.
Bancel said he could not comment further on the patent case because it was an open matter, but said simply making the recipes available would not make the vaccine available enough. “No industry in the world is looking forward to doing so,” said Bancel, “because the industry does not exist. It’s a new kind of thing.
Commenting on why Moderna is looking at profits, he said, “if you can imagine, to get new delivery items you need a lot of money.” While Moderna received billions of dollars from the US government to support her research as part of Operation Warp Speed, Bancel said the money would not come from developing the technology to develop her new vaccine. After governments and foundations indicated they did not want to invest, the company had to go to major markets to raise about $ 5 billion. He says that in order to encourage people to invest in these types of investments, they often have to believe that there will be economic benefits.
To him, Bhadelia doesn’t think it’s a / or a problem. He thinks I am earning money to ensure that companies make a profit to continue their research, and in response to the global health call for an epidemic that has killed at least 5 million people. The similarity of the vaccine is a very important factor. “There are still some places in the world where only 5 percent of the population has been vaccinated,” he said, as in the US people get second or third levels and start vaccinating children before the holidays.
One solution is to make life-saving vaccines cheaper worldwide. For poor countries, 70 percent of their health care spending goes on vaccination. In the US, it has traditionally been less than 1 percent. Bhadelia acknowledges that there are many other barriers to getting the vaccine they need, but availability is one of them.
[ad_2]
Source link
